|
|
 |
Central nervous system agent
|
 |
Antiemetic/antivertigo agent
|
 |
For the prevention and treatment of nausea, vomiting, or dizziness associated with motion sickness.
|
 |
Adults: 25 to 100 mg/day in divided doses. For motion sickness, take 2 5mg-50 mg 1 hour prior to travel. May repeat daily for the course of travel.
|
 |
Category B
|
 |
Drowsiness, dry mouth, and blurred vision.
|
Pregnancy Risk Categories defined:
A: Studies in pregnant women failed to show a risk to the fetus in the first
trimester - with no evidence of risk in the later trimesters.
B: Animals studies indicate no adverse effect to the fetus, but there are no adequate,
clinical studies in pregnant women.
C: Animal studies have shown an adverse effect on the fetus, but there are no adequate,
clinical studies in humans. Despite potential risks, the drug may be useful in pregnant
women.
D: There is evidence of risk to the human fetus, but the potential benefits of use in
pregnant women may be acceptable, despite potential risks.
X: Studies in animals or humans show fetal abnormalities, or adverse reaction reports
indicate evidence of fetal risk. Warning: the risks involved clearly outweigh any
potential benefit from using the drug in pregnant women, regardless of trimester.
NR: Not rated (i.e., no information available at this time as to the potential
risks or benefits).
|
| | |
If you want your friend to read or know about this article, Click here
 |
|
|
